Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial
January 2012
in “
Journal of Clinical & Experimental Dermatology Research
”
This study investigated the effect of fexofenadine as an adjunct to diphenylcyclopropenone (DPCP) in 100 non-atopic patients with Alopecia areata (AA) experiencing more than 25% scalp hair loss. Patients were divided into two groups: one received both DPCP and oral fexofenadine, while the other received only DPCP. Although hair regrowth was better in the group receiving fexofenadine, the difference was not statistically significant. However, the group receiving fexofenadine experienced significantly less eczematous reaction and pruritus, suggesting that while fexofenadine did not enhance hair regrowth, it improved patient compliance by reducing the discomfort associated with DPCP treatment.